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OBJECTIVES: To evaluate the health care cost for the management of diabetes
along with other co-morbidities condition before and after counseling. METHODS:
A Prospective interventional study was conducted in the community setup of
Warangal, India for a period of four months. Only the educated Diabetic patients
with other comorbidities were enrolled in the study. The data collected were cost of
medications, lab tests, consultation fee, transportation cost. The average total
health care cost was calculated based on the previous two months expenses of
each patient before and after counseling. RESULTS: A total of 100 patients were
evaluated in the study period. Out of 100 patients, majorities were in the age group
of 41-61 yrs 66(66%) and men 63(63%) followed by women 37(37%). Most of the
patients were diabetes with hypertension, dyslipidemia. The average cost of med-
ications per patient Rs. 1540(72.81%), the average laboratory cost per patient Rs.
350(16.55%), the average doctors consultation fee per patient Rs.175(8.27%), the
average transportation charges per patient Rs.50(2.36%). The most common drugs
prescribed in the study were Metformin, Glibenclamide, Gliclazide, Insulin,
Ramipril, Amlodipine, Telmisartan, Metoprolol, Hydrochlorothiazide, Furosemide,
Atorvastatin and Aspirin. The most common laboratory test includes FBS/PPBS/
RBS/HbA1C, lipid profiles, urine analysis, Hb, Electrolytes and Sr.Creatinine. The
average total health care cost for two months before and after counseling was
found to be Rs.2115 and Rs.1755 per patient.CONCLUSIONS: In summary this is the
first Indian health care cost study conducted in the community setup. Our study
result shows that there is decreased cost for the management of diabetes along
with other co-morbidities condition after the counseling by 17% to 18% after the
two months follow up. So more prevention efforts and resources are required to
reduce this burden and to provide basic diabetes care in the low- and middle-
income countries.
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OBJECTIVES: With the introduction of the bundled payment model in 2007, a large
number of disease management programs (DMP) were initiated in the Netherlands.
It is hypothesized that bundled payment will improve the quality of care en en-
courages tasks delegation and substitution. As result, health care costs may de-
crease resulting in efficiency improvement of diabetes care. METHODS: We ana-
lyzed insurance claim payments of 24 different insurance agencies of the
Netherlands using data of Vektis. Data of 52 care groups, covering about 50% of the
diabetes type 2 population were used. In total, 61,497 diabetes type 2 patients,
clustered in 3078 GPs, were analyzed in a longitudinal multi-level design. For two
years 32% of the patients (or their GPs) were enrolled in a DMP based on bundled
payment and 21% in a DMP based on management fee whereas the patients of the
control group (47%) stayed in ‘care-as-usual’ (CAU). RESULTS: Results show in-
creasing curative health care costs of Euro 219 per patient from 2008 to 2009. While
controlling for age, sex, comorbidity, and costs at baseline (average yearly costs in
2008 were Euro 4123), the average costs per patient enrolled in DMP based on
bundled payment increased with Euro 288 more compared to CAU. The increase of
costs of DMP based on management fee was not significant different from CAU. The
increase in costs did not vary between health insurance agencies or GPs. Sensitivity
analyses were conducted with a much smaller and therefore less useful 3-year data
set. Substantive conclusions remained the same. CONCLUSIONS: Results showed
an increase in curative health care costs of diabetes patients caused by DMP based
on bundled payment over a period of 2 years. Further research should investigate a
longer time-span to study long-term effects of DMP on costs.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The primary objective of the
analysis was to determine the direct cost components caused by T2DM and its
complications. The relationship between metabolic complications and cost com-
ponents is reported in this presentation. METHODS: Forty centres were selected
from the list of centres in which adult T2DM patients were followed on a routine
basis. These centres were representative of the country, since they were selected
by two-stage cluster sampling. Medical files were reviewed for two to five years
prior to the study. Item prices were obtained from the Ministry of Health and Social
Security Organization of Turkey. Costs are calculated simply as the total of all
frequency-price products (1€  2.321 Turkish Liras; Feb 2012). RESULTS: A total of
942 patients’ data were included in the analysis. During the previous five years,
28.0% of the patients had at least one visit or hospital stay related to metabolic
complications (incl. diabetic ketoacidosis, hyperglycemic hyperosmolar state, hy-
poglycemia) and poor glycemic control. Total annual costs were 549.46€ and
364.52€, in patients with and without metabolic complications, respectively. Costs
related to treatment, laboratory tests and health care services were 270.46€, 61.49€
and 32.57€, respectively, in patients without metabolic complications. Whereas
costs related to treatment, laboratory tests and health care services were signifi-
cantly higher in patients with metabolic complications (383.90€, 88.93€ and 76.64€,
respectively; all p-values0.01). CONCLUSIONS: All components of cost increased
by 35% to 135% with the presence of metabolic complications. Whatever this rela-
tionship is based on (whether a direct association between acute metabolic status
and the costs or an indirect association via the relationship between metabolic
control and systemic complications), better metabolic control will significantly
lower the cost of management of DM.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The relationship between
chronic long-term complications (i.e. cardiovascular, neurologic, ophthalmic etc)
and cost components is reported in this presentation. METHODS: Forty centres
were selected from the list of centres in which adult T2DM patients were followed
on routine basis. These centres were representative of the country, since they were
selected by two-stage cluster sampling. Medical files were reviewed for two to five
years prior to the study. Collected data included health care utilization items (med-
ical and surgical treatments, laboratory tests, inpatient/outpatient visits, consul-
tations and patient education). Item prices were obtained from the Ministry of
Health and Social Security Organization of Turkey (1€  2.3210 Turkish Liras; Feb
2012). RESULTS:A total of 942 patients’ data were included in the analysis. In 63.7%
of the patients, no visits related to any diabetic complication had been recorded,
thus these patients were regarded as patients without complication. The propor-
tions of patients with one, two and more than two complications were 25.8%, 7.9%
and 2.6%, respectively. Total annual cost, which was found to be 324.27€ in patients
with no systemic complication increased to 512.78€, 641.94€, 817.84€ and 1835.06€
with increasing number of systems involved (from one system to four systems).
CONCLUSIONS: The cost of DM is strongly related with the number of systems
involved by diabetic complications. Since the prevalence of DM is quite high and is
further increasing, prevention and/or delay of complications will be crucial to re-
duce the economic burden of diabetes on the general health care budget. [Integrat-
ing the costs from this analysis and the epidemiologic data from a recently updated
local study (TURDEP-II), a burden of disease model will be developed and distrib-
uted soon].
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OBJECTIVES: Type 2 diabetes imposes a substantial economic burden on society.
The objective of this study was to quantify the association between health care
costs attributable to diabetes and level of glycemic control.METHODS:A retrospec-
tive analysis using a large administrative database and a clinical registry contain-
ing laboratory results was performed. Subjects, aged  45, were diagnosed for
diabetes in 2008 and assigned to one of the 5 groups based upon the percentage of
HbA1c values  7% over the 2-years of follow-up after diagnosis: 80% (excellent-
control), 79%-60% (good), 59%-40% (fair), 39%-20% (poor), 20% (very-poor). The
cost attributable to oral antidiabetic drugs (OAD) and the direct cost due to hospi-
talizations or outpatient services for diabetes or cardiovascular disease were ana-
lyzed. Multivariate analysis was used to control for differences in potential con-
founding factors including age, sex, use of dyslipidemia drugs, use of hypertension
drugs, previous cardiovascular disease and OAD adherence level among the study
groups. RESULTS: Of 8,123 patients included, HbA1c control was excellent in 2,359
(29.0%) patients, good in 870 (10.7%), fair in 853 (10.5%), poor in 998 (12.3%) and
very-poor in 3,043 (37,5%). Adherence to OAD was higher among suboptimal gly-
cemic control patients (from 45.3% in the excellent-control group to 63.9% in the
very-poor control group). Over 2 years, the mean diabetes-related cost was:
€1,947.46 in the excellent-control group; €2,030.68 in that with a good-control; €
2,241.33 with a fair-control; € 2,489.04 with a poor-control; €2,216.75 with a very-
poor-control. After adjustment, the estimated excess cost associated with good-
control, fair-control, poor-control and very-poor-control group was €207.65;
€381.03; €682.28; €417.81 respectively. CONCLUSIONS: Almost half (49.8%) patients
in this study showed a sub-optimal glycemic control. This analysis indicates that
the diabetes-related costs are significantly higher for individuals who have a poor
glycemic control compared with those patients who have an excellent glycemic
control.
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OBJECTIVES: This study explored the pattern and cost of medicines prescribed at a
diabetic clinic in Ho Municipal Hospital, Volta Region, Ghana. METHODS: Cross
sectional in design. A retrospective sampling procedure was used to collect data.
100 computer generated prescriptions were randomly selected from the computer
data base for all OPD cases visiting the diabetic clinic in Ho Municipal Hospital
between the periods of January 1 to December 31, 2011. With the aid of Excel and
SPSS (vers 20), the data generated was analyzed and appropriate measures of cen-
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